文献速递乳腺癌

EORTC 22922/10925 试验 20 年结果:内乳与锁骨上内侧淋巴结照射

Twenty-year results of the randomized European Organization for Research and Treatment of Cancer trial 22922/10925 evaluating internal mammary chain and medial supraclavicular lymph node irradiation in stage I-III breast cancer.
PubMed 文献 · CA Cancer J Clin · 2026-01-01

EORTC 22922/10925 随机试验纳入 4004 例 I-III 期乳腺癌患者,评估内乳及锁骨上内侧淋巴结照射(IM-MS-RT)的长期疗效。

要点

  • IM-MS-RT 未改善 20 年总生存、无病生存或远处转移无生存。
  • IM-MS-RT 显著降低乳腺癌死亡率(22.4% vs 18.6%,HR 0.82)。
  • IM-MS-RT 增加非乳腺癌死亡及肺纤维化、心脏疾病等晚期毒性。

核心结论

  • IM-MS-RT 使 20 年乳腺癌死亡率显著降低,但非乳腺癌死亡增加,总生存无长期获益。

研究设计与样本

  • 随机对照试验 EORTC 22922/10925,1996-2004 年纳入 4004 例 I-III 期乳腺癌患者,中位年龄 54 岁。
  • 入组条件为腋窝淋巴结阳性或中央/内侧肿瘤(不论淋巴结状态),随机接受 IM-MS-RT 或不照射。

主要发现

  • 中位随访 22.2 年,共 1550 例(38.7%)死亡,其中 796 例(51.4%)死于乳腺癌。
  • IM-MS-RT 组肺纤维化(6.3% vs 3.2%)、心脏纤维化(2.7% vs 1.7%)和心脏疾病(15.2% vs 11.7%)更常见。

关键数值与推荐

  • 主要终点为总生存,次要终点包括无病生存、远处转移无生存、乳腺癌死亡率和任何乳腺复发。
  • 严重心脏和肺毒性(评分 3 或 4)率分别为 1.9% vs 1.7% 和 0.3% vs 0.0%。

临床怎么用

  • 对预后较好的乳腺癌患者,IM-MS-RT 需权衡乳腺癌死亡率下降与晚期非乳腺癌死亡及心肺毒性增加。
  • 临床决策应个体化,并重视长期随访以评估晚期毒性对总生存的影响。

局限性

  • 原文未明确报告研究局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

European Organization for Research and Treatment of Cancer trial EORTC 22922/10925 evaluated internal mammary and medial supraclavicular (IM-MS) lymph node irradiation (IM-MS-RT) in patients with stage I-III breast cancer. Eligible patients had involved axillary nodes and/or centrally/medially located tumors regardless of nodal involvement. The primary end point was overall survival, secondary end points were disease-free survival, distant metastases-free survival, breast cancer mortality, and any breast recurrence. Between 1996 and 2004, 4004 patients were randomized. The median patient age was 54 years. At a median follow-up of 22.2 years, 1550 (38.7%) patients died, of whom 796 (51.4%) died from breast cancer. At 20 years, the overall survival rate was 61.8% in the control group versus 61.0% in the IM-MS-RT group (hazard ratio [HR], 1.00; p = .967); the disease-free survival rate was 49.0% versus 48.2%, respectively (HR, 0.97; p = .515); and the distant metastases-free survival rate was 59.8% versus 58.9%, respectively (HR, 0.97; p = .578). The breast cancer mortality rate was 22.4% in the control group and 18.6% in the IM-MS-RT group (HR, 0.82; p = .006), whereas the rate of deaths not from breast cancer or from unknown causes was 15.8% versus 20.4%, respectively (HR, 1.26; p = .002). Lung fibrosis, cardiac fibrosis, and cardiac diseases were more frequent after IM-MS-RT versus no IM-MS-RT (6.3% vs. 3.2%, 2.7% vs. 1.7%. and 15.2% vs. 11.7%, respectively); and the rates of severe cardiac and lung morbidities (scores of 3 or 4) were 1.9% versus 1.7% and 0.3% versus 0.0%, respectively. Breast cancer mortality at 20 years was statistically significantly lower after IM-MS-RT, but deaths not from breast cancer increased after 15 years, resulting in no long-term benefit of IM-MS-RT on overall survival. Therefore, the authors strongly call for very long-term follow-up of treatments for prognostically favorable cancers such as breast cancer.

来源:CA Cancer J Clin,查看原文。版权归原作者所有。

引用

  1. Kaidar-Person O, Weltens CG, Fortpied C, et al. Twenty-year results of the randomized European Organization for Research and Treatment of Cancer trial 22922/10925 evaluating internal mammary chain and medial supraclavicular lymph node irradiation in stage I-III breast cancer. CA Cancer J Clin. 2026. PMID: 42141924. doi:10.3322/caac.70082

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。